Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Veracyte (DE:12V)
FRANKFURT:12V
Holding DE:12V?
Track your performance easily
12V Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€17.50 - €31.60
Previous Close€31.6
Volume1.00
Average Volume (3M)77.00
Market Cap
€2.43B
Enterprise Value€2.24B
Total Cash (Recent Filing)$235.91M
Total Debt (Recent Filing)$20.74M
Price to Earnings (P/E)―
Beta1.20
Next Earnings
Nov 06, 2024EPS Estimate
€0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding76,812,124
10 Day Avg. Volume0
30 Day Avg. Volume77
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)2.13
Price to Sales (P/S)6.60
Price to Cash Flow (P/CF)22.30
P/FCF Ratio24.60
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.60
Enterprise Value/Gross Profit9.01
Enterprise Value/Ebitda-394.47
Forecast
1Y Price Target
€34.02Price Target Upside7.66% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Veracyte News
PremiumCompany Announcements
Veracyte Announces Expansion of Board with New AppointeesBulls Say, Bears Say
Bulls Say
Financial PerformanceVCYT's revenue growth improved to 26.7% from 17.5% driven by strong Decipher and Afirma testing growth.
ProfitabilityNon-GAAP gross margin was up 350 basis points and non-GAAP EBITDA margin was up 880 basis points as VCYT progresses towards sustained profitability.
Revenue GuidanceVCYT increased its FY24 revenue guidance to $402-$410 million from the previous estimate of $394-$402 million.
Bears Say
Gross MarginNon-GAAP gross margin was down 70 bps Y/Y.
Product RevenueProduct revenue (Prosigna) declined 9%, driven by continued efforts to move supplier.
Revenue GrowthRevenue growth slowed to 17.5% Y/Y in 1Q24 from 22.3% in 4Q23 as strong Testing growth was partially offset by declines in both Biopharma and Other revenue and Product revenue.
---
Options Prices
Currently, No data available
---
Ownership Overview
1.33% Insiders
32.50% Mutual Funds
0.26% Other Institutional Investors
40.42% Public Companies and
Individual Investors
12V FAQ
What was Veracyte’s price range in the past 12 months?
Veracyte lowest stock price was €17.50 and its highest was €31.60 in the past 12 months.
What is Veracyte’s market cap?
Currently, no data Available
When is Veracyte’s upcoming earnings report date?
Veracyte’s upcoming earnings report date is Nov 06, 2024 which is in 18 days.
How were Veracyte’s earnings last quarter?
Veracyte released its earnings results on Aug 06, 2024. The company reported €0.064 earnings per share for the quarter, beating the consensus estimate of -€0.015 by €0.079.
Is Veracyte overvalued?
According to Wall Street analysts Veracyte’s price is currently Undervalued.
Does Veracyte pay dividends?
Veracyte does not currently pay dividends.
What is Veracyte’s EPS estimate?
Veracyte’s EPS estimate is €0.03.
How many shares outstanding does Veracyte have?
Veracyte has 76,812,126 shares outstanding.
What happened to Veracyte’s price movement after its last earnings report?
Veracyte reported an EPS of €0.064 in its last earnings report, beating expectations of -€0.015. Following the earnings report the stock price went up 22.105%.
Which hedge fund is a major shareholder of Veracyte?
Among the largest hedge funds holding Veracyte’s share is ARK Investment Management LLC. It holds Veracyte’s shares valued at 148M.
---
Veracyte Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€34.02 (7.66% Upside)
€34.02 (7.66% Upside)
Blogger Sentiment
Bullish
DE:12V Sentiment 100%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
59.43%
12-Months-Change
Fundamentals
Return on Equity
-4.88%
Trailing 12-Months
Asset Growth
6.31%
Trailing 12-Months
Company Description
Veracyte
Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.
---
12V Company Deck
---
12V Earnings Call
Q2 2024
0:00 / 0:00
---
12V Stock 12 Month Forecast
Average Price Target
€34.02
▲(7.66% Upside)
Technical Analysis
Best Analysts Covering 12V
1 Year
1 Year Success Rate
15/20 ratings generated profit
1 Year Average Return
+49.82%
reiterated a buy rating 20 days ago
Copying Sung Ji Nam's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +49.82% per trade.
---